147 related articles for article (PubMed ID: 38417050)
1. Role of glutaminyl-peptide cyclotransferase in breast cancer doxorubicin sensitivity.
Xu B; Yang L; Yang L; Al-Maamari A; Zhang J; Song H; Wang M; Su S; Song Z
Cancer Biol Ther; 2024 Dec; 25(1):2321767. PubMed ID: 38417050
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
Abdin SM; Tolba MF; Zaher DM; Omar HA
Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
[TBL] [Abstract][Full Text] [Related]
3. Molecular Modification of Metadherin/MTDH Impacts the Sensitivity of Breast Cancer to Doxorubicin.
Song Z; Wang Y; Li C; Zhang D; Wang X
PLoS One; 2015; 10(5):e0127599. PubMed ID: 25993398
[TBL] [Abstract][Full Text] [Related]
4. DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-κB-HIF1α axis.
Neeli PK; Sahoo S; Karnewar S; Singuru G; Pulipaka S; Annamaneni S; Kotamraju S
FEBS J; 2023 Jan; 290(2):502-520. PubMed ID: 36017623
[TBL] [Abstract][Full Text] [Related]
5. Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells.
Zhao Y; Kong X; Li X; Yan S; Yuan C; Hu W; Yang Q
PLoS One; 2011; 6(12):e29363. PubMed ID: 22195048
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
7. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
[TBL] [Abstract][Full Text] [Related]
8. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
van Wijngaarden J; van Beek E; van Rossum G; van der Bent C; Hoekman K; van der Pluijm G; van der Pol MA; Broxterman HJ; van Hinsbergh VW; Löwik CW
Eur J Cancer; 2007 Jan; 43(2):433-42. PubMed ID: 17097285
[TBL] [Abstract][Full Text] [Related]
10. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
11. A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
Xie C; Zhang LZ; Chen ZL; Zhong WJ; Fang JH; Zhu Y; Xiao MH; Guo ZW; Zhao N; He X; Zhuang SM
Hepatology; 2020 May; 71(5):1660-1677. PubMed ID: 31509261
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Metadherin on NF-κB Activation and Downstream Genes in Ovarian Cancer.
Rong C; Shi Y; Huang J; Wang X; Shimizu R; Mori Y; Murai A; Liang J
Cell Transplant; 2020; 29():963689720905506. PubMed ID: 32207338
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of glutaminyl-peptide cyclotransferase(QPCT)in Scylla paramamosain and its role in Vibrio alginolyticus and white spot syndrome virus (WSSV) infection.
Wang Z; Sun B; Zhu F
Fish Shellfish Immunol; 2018 Jul; 78():299-309. PubMed ID: 29709591
[TBL] [Abstract][Full Text] [Related]
15. MiR-524 suppressed the progression of oral squamous cell carcinoma by suppressing Metadherin and NF-κB signaling pathway in OSCC cell lines.
Chang XS; Zhu J; Yang T; Gao Y
Arch Oral Biol; 2021 May; 125():105090. PubMed ID: 33676362
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
17. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
18. SENP2 suppresses NF-κB activation and sensitizes breast cancer cells to doxorubicin.
Gao X; Wu Y; Qiao L; Feng X
Eur J Pharmacol; 2019 Jul; 854():179-186. PubMed ID: 30940449
[TBL] [Abstract][Full Text] [Related]
19. The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.
Zhang N; Wang X; Huo Q; Li X; Wang H; Schneider P; Hu G; Yang Q
J Biol Chem; 2013 Mar; 288(13):9396-407. PubMed ID: 23408429
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
